Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
McKinsey
Express Scripts
Baxter
Harvard Business School

Last Updated: February 2, 2023

EPZICOM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Epzicom, and what generic alternatives are available?

Epzicom is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in EPZICOM is abacavir sulfate; lamivudine. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.

Paragraph IV (Patent) Challenges for EPZICOM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EPZICOM Tablets abacavir sulfate; lamivudine 600 mg/300 mg 021652 1 2007-09-27

US Patents and Regulatory Information for EPZICOM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EPZICOM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 See Plans and Pricing See Plans and Pricing
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 See Plans and Pricing See Plans and Pricing
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 See Plans and Pricing See Plans and Pricing
Viiv Hlthcare EPZICOM abacavir sulfate; lamivudine TABLET;ORAL 021652-001 Aug 2, 2004 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for EPZICOM

See the table below for patents covering EPZICOM around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 0479822 NUCLEOSIDES THERAPEUTIQUES (THERAPEUTIC NUCLEOSIDES) See Plans and Pricing
Australia 7771991 See Plans and Pricing
Canada 2289655 See Plans and Pricing
Russian Federation 2092485 1,3-OXATHIOLANE, GEOMETRICAL AND OPTICAL ISOMERS THEREOF, MIXTURES OF SAID ISOMERS, METHODS OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION HAVING ANTIVIRAL ACTIVITY See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for EPZICOM

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0817637 SPC016/2005 Ireland See Plans and Pricing SPC016/2005: 20060407, EXPIRES: 20191216
0817637 C00817637/01 Switzerland See Plans and Pricing PRODUCT NAME: ABACAVIR + LAMIVUDIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 56977 31.10.2005
0817637 SPC/GB05/027 United Kingdom See Plans and Pricing SPC/GB05/027: 20050922, EXPIRES: 20191216
0382526 SPC/GB96/043 United Kingdom See Plans and Pricing PRODUCT NAME: LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: CH 53662 19960228; CH 53663 19960228; UK EU/1/96/015/001 19960808; UK EU/1/96/015/002 19960808
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Baxter
Express Scripts
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.